18F-FDG PET/CT预测非小细胞肺癌患者EGFR突变和ALK阳性表达的价值:849例中国患者的回顾性分析
回顾性纳入849例治疗前接受18F-FDG PET/CT且检测EGFR突变或ALK状态的NSCLC患者,EGFR突变371例(45.9%)。多因素分析显示pSUVmax<7.0、女性、非吸烟者和腺癌是EGFR突变的预测因素;低pSUVmax与突变型EGFR状态相关,可与其它临床因素整合以提高部分无法进行EGFR检测患者的判别能力。
要点
- 849例NSCLC患者中EGFR突变371例(45.9%),低pSUVmax与EGFR突变显著相关
- pSUVmax<7.0、女性、非吸烟者和腺癌是多因素分析中EGFR突变的预测因素
- 低pSUVmax单独及四因素联合的ROC曲线AUC分别为0.557和0.697
核心结论
- 低pSUVmax与突变型EGFR状态相关,可与其它临床因素整合以提高部分无法进行EGFR检测的NSCLC患者对EGFR突变状态的判别能力。
研究设计与样本
- 回顾性分析纳入849例治疗前接受18F-FDG PET/CT且检测EGFR突变或ALK状态的NSCLC患者。
- 比较不同亚组间临床特征及基于18F-FDG PET/CT的三个参数(原发肿瘤SUVmax即pSUVmax、淋巴结SUVmax即nSUVmax、远处转移SUVmax即mSUVmax)的差异。
- 采用多因素逻辑回归分析识别EGFR突变和ALK阳性的预测因素。
主要发现
- 371例患者(45.9%)检出EGFR突变,EGFR突变在女性、非吸烟者、腺癌和I期疾病中更常见。
- 低pSUVmax、nSUVmax和mSUVmax与EGFR突变显著相关。
- 多因素分析显示pSUVmax<7.0、女性、非吸烟者和腺癌是EGFR突变的预测因素。
- ROC曲线显示低pSUVmax单独和四因素联合的AUC分别为0.557和0.697。
- ALK阳性患者倾向于具有高nSUVmax,年轻年龄和远处转移是ALK阳性的仅有两个独立预测因素。
关键数值与推荐
- pSUVmax<7.0、女性、非吸烟者和腺癌为EGFR突变的预测因素。
- 低pSUVmax单独预测EGFR突变的AUC为0.557,四因素联合的AUC为0.697。
- 年轻年龄和远处转移是ALK阳性的独立预测因素。
临床怎么用
- 作者认为低pSUVmax可与其它临床因素整合,以提高部分无法进行EGFR检测的NSCLC患者对EGFR突变状态的判别能力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Epidermal growth factor receptor (EGFR) mutations and the anaplastic lymphoma kinase (ALK) rearrangement are the two most common druggable targets in non-small cell lung cancer (NSCLC). However, genetic testing is sometimes unavailable. Previous studies regarding the predictive role of 18F-FDG PET/CT for EGFR mutations in NSCLC patients are conflicting. We investigated whether or not 18F-FDG PET could be a valuable noninvasive method to predict EGFR mutations and ALK positivity in NSCLC using the largest patient cohort to date. METHODS: We retrospectively reviewed and included 849 NSCLC patients who were tested for EGFR mutations or ALK status and subjected to 18F-FDG PET/CT prior to treatment. The differences in several clinical characteristics and three parameters based on 18F-FDG PET/CT, including the maximal standard uptake value (SUVmax) of the primary tumor (pSUVmax), lymph node (nSUVmax) and distant metastasis (mSUVmax), between the different subgroups were analyzed. Multivariate logistic regression analysis was performed to identify predictors of EGFR mutations and ALK positivity. RESULTS: EGFR mutations were identified in 371 patients (45.9%). EGFR mutations were found more frequently in females, non-smokers, adenocarcinomas and stage I disease. Low pSUVmax, nSUVmax and mSUVmax were significantly associated with EGFR mutations. Multivariate analysis demonstrated that pSUVmax < 7.0, female sex, non-smoker status and adenocarcinoma were predictors of EGFR mutations. The receiver operating characteristic (ROC) curve yielded area under the curve (AUC) values of 0.557 and 0.697 for low pSUVmax alone and the combination of the four factors, respectively. ALK-positive patients tended to have a high nSUVmax. Younger age and distant metastasis were the only two independent predictors of ALK positivity. CONCLUSION: We demonstrated that low pSUVmax is associated with mutant EGFR status and could be integrated with other clinical factors to enhance the discriminability on the EGFR mutation status in some NSCLC patients whose EGFR testing is unavailable.
引用
- Lv Z, Fan J, Xu J, et al. Value of 18F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients. Eur J Nucl Med Mol Imaging. 2017. PMID: 29164298. doi:10.1007/s00259-017-3885-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。